A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID)
Title:
A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID)
Author:
Viallard, J.-F. Brion, J.-P. Malphettes, M. Durieu, I. Gardembas, M. Schleinitz, N. Hoarau, C. Lazaro, E. Puget, S.
Appeared in:
Revue de medecine interne
Paging:
Volume 38 (2017) nr. 9 pages 7 p.
Year:
2017
Contents:
Publisher:
Société Nationale Française de Médecine Interne (SNFMI)